search
Back to results

Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes

Primary Purpose

Gestational Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Insulin LISPRO
Insulin, Long-Acting and Insulin
Sponsored by
Sansum Diabetes Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gestational Diabetes Mellitus focused on measuring gestational diabetes mellitus, insulin analogues in pregnancy

Eligibility Criteria

18 Years - 44 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Pregnant and at least 13 weeks gestation
  • Diagnosed with gestational diabetes mellitus
  • Failed diet therapy

Exclusion Criteria:

  • <18 years old or over 45 years old
  • urine dipstick >2+ protein
  • blood pressure >140/80 mmHg
  • hematocrit <30%
  • refusal to take insulin
  • inability to understand instructions or to consent to participate.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Mix 50/50

    Usual insulin regimen

    Arm Description

    Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.

    Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime

    Outcomes

    Primary Outcome Measures

    Hemoglobin A1C
    Compare the efficacy and safety of three daily injections of Humalog® Mix50/50TM to six daily injections of Humalog® and Humulin N® insulin, by hemoglobin A1C.

    Secondary Outcome Measures

    Birthweight of Infant
    Birthweight of infant born to mother with gestational diabetes using insulin

    Full Information

    First Posted
    June 5, 2012
    Last Updated
    June 7, 2022
    Sponsor
    Sansum Diabetes Research Institute
    Collaborators
    Eli Lilly and Company
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01613807
    Brief Title
    Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes
    Official Title
    Phase 4 Humalog® Mix50/50(tm) for the Treatment of Insulin Requiring Gestational Diabetes
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2008 (undefined)
    Primary Completion Date
    June 2010 (Actual)
    Study Completion Date
    October 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Sansum Diabetes Research Institute
    Collaborators
    Eli Lilly and Company

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Evaluation of the Safety and Efficacy of Humalog® Mix50/50TM administered as 3 injections daily to Humalog® plus Humulin N® insulin administered as 6 separate injections daily in terms of glucose control for women with Gestational Diabetes.
    Detailed Description
    Controlling hyperglycemia during pregnancy decreases the risk of adverse neonatal and maternal outcomes. Not only must fasting glucose be normalized, but clinical evidence also indicates that controlling postprandial hyperglycemia will significantly reduce the risk of adverse neonatal and maternal outcomes. Standard therapy to achieve near-normal glycemia in gestational diabetes involves combining intermediate-acting basal (NPH) insulin with rapid-acting insulin (insulin lispro), thereby requiring 6 daily injections. Premixed Humalog® Mix50/50TM has the potential advantage over combination rapid-acting plus NPH insulin because it involves fewer injections, and those injections are associated with mealtime. The potential downside to the premixed formulation is nocturnal hypoglycemia associated with the time lag between the dinner and breakfast dose. This study will evaluate the efficacy and safety of Humalog® Mix50/50TM compared to that of Humalog® plus Humulin N® insulin for the treatment of insulin-requiring patients with gestational diabetes mellitus, while monitoring glucose control, intrauterine growth and assessing pregnancy outcomes.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gestational Diabetes Mellitus
    Keywords
    gestational diabetes mellitus, insulin analogues in pregnancy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    40 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Mix 50/50
    Arm Type
    Experimental
    Arm Description
    Insulin LISPRO: 3 doses of Humalog® Mix50/50™ at mealtime.
    Arm Title
    Usual insulin regimen
    Arm Type
    Active Comparator
    Arm Description
    Usual insulin regimen of insulin, Long-Acting and Insulin: 3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
    Intervention Type
    Drug
    Intervention Name(s)
    Insulin LISPRO
    Other Intervention Name(s)
    Humalog® Mix50/50™
    Intervention Description
    Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
    Intervention Type
    Drug
    Intervention Name(s)
    Insulin, Long-Acting and Insulin
    Other Intervention Name(s)
    Humalin N(r), Humalog (r)
    Intervention Description
    Usual insulin regimen: Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
    Primary Outcome Measure Information:
    Title
    Hemoglobin A1C
    Description
    Compare the efficacy and safety of three daily injections of Humalog® Mix50/50TM to six daily injections of Humalog® and Humulin N® insulin, by hemoglobin A1C.
    Time Frame
    During Pregnancy (at approximately 28 weeks gestation)
    Secondary Outcome Measure Information:
    Title
    Birthweight of Infant
    Description
    Birthweight of infant born to mother with gestational diabetes using insulin
    Time Frame
    End of pregnancy

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    44 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Pregnant and at least 13 weeks gestation Diagnosed with gestational diabetes mellitus Failed diet therapy Exclusion Criteria: <18 years old or over 45 years old urine dipstick >2+ protein blood pressure >140/80 mmHg hematocrit <30% refusal to take insulin inability to understand instructions or to consent to participate.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Kristin Castorino, DO
    Organizational Affiliation
    Sansum Diabetes Research Institute
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes

    We'll reach out to this number within 24 hrs